| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BRD4 |
| Uniprot No | O60885 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 49-170aa |
| 氨基酸序列 | ETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYY KIIKTPMDMGTIKKRLENNYYWNAQECIQDFN TMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETE |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BRD4重组蛋白的3篇代表性参考文献：
1. **文献名称**：*Selective inhibition of BET bromodomains*
**作者**：Filippakopoulos, P. et al.
**摘要**：该研究解析了BRD4重组蛋白的溴结构域晶体结构，并开发了选择性抑制剂JQ1.揭示其通过竞争性结合溴结构域阻断转录调控的机制。
2. **文献名称**：*Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression*
**作者**：Yang, Z. et al.
**摘要**：利用重组BRD4蛋白进行体外互作实验，证明BRD4通过招募P-TEFb复合物到染色质，调控细胞周期G1期关键基因转录。
3. **文献名称**：*Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of hexokinase 2*
**作者**：Zhang, X. et al.
**摘要**：研究通过重组BRD4蛋白及抑制剂处理，阐明BRD4通过调控糖酵解酶HK2表达促进非小细胞肺癌增殖的分子机制。
(注：上述文献为示例性内容，实际引用时请核对原文准确性。)
BRD4. a member of the bromodomain and extraterminal (BET) protein family, is a chromatin-associated transcriptional regulator playing pivotal roles in cell cycle progression, epigenetic memory, and inflammatory responses. It contains two bromodomains (BD1 and BD2) that recognize acetylated lysine residues on histones, facilitating its recruitment to acetylated chromatin regions. This interaction enables BRD4 to recruit transcriptional regulators, such as the positive transcription elongation factor b (P-TEFb), to promote RNA polymerase II-dependent gene expression. Dysregulation of BRD4 is implicated in cancers, inflammatory diseases, and viral pathogenesis, making it a key therapeutic target.
Recombinant BRD4 proteins are engineered in vitro to study its molecular functions and screen inhibitors. Typically produced in bacterial (e.g., *E. coli*) or eukaryotic expression systems, these proteins retain functional bromodomains and are purified using affinity tags (e.g., His-tag). Recombinant BRD4 serves as a tool for structural studies (e.g., X-ray crystallography), biochemical assays (e.g., binding kinetics with acetylated peptides or inhibitors like JQ1), and high-throughput drug screening. It also aids in elucidating BRD4’s role in diseases, such as its oncogenic fusion in NUT midline carcinoma or its involvement in MYC-driven cancers. Additionally, recombinant BRD4 is used to explore its non-canonical roles, including DNA damage repair and immune regulation. The development of BET inhibitors, many targeting BRD4. underscores its clinical relevance in precision medicine.
×
